Gapping up
In reaction to strong earnings/guidance: JRJC +34.9%, HEI +5.2%, VRX +2.4%, HON +1.5%
M&A news: ANAD +24.3% (has determined that a new offer of $0.48/share is superior to the GaAs Labs transaction)FVE +11.8% (6.1% holder William F. Thomas/Gemini Properties disclosed proposal to FVE to acquire 33 facilities and explore strategic alternatives), HPY +10.4% (Heartland Payment Systems to be acquired by Global Payments for $4.3 bln, or $100.00 per share)
Select financial Solar names showing strength after House Republicans are pushing forward a bill lifting the ban on crude oil exports, including an extended tax credit for wind an solar: RUN +14.9%, SUNE +14.1%, PLUG +8%, SPWR +6.5%, FSLR +6.3%, CSIQ +3.9%, SOL +3.1%, ETP +3%, TSL +2.1%
Select metals/mining stocks trading higher: BHP +3.4%, BBL +3.2%, FCX +2.3%, RIO +2.3%, ABX +1.5%, SLW +0.8%
Select Heathcare related names showing strength in Europe: SHPG +2.9%, GSK +1.7%, NVS +1.1%, AZN +1.1%
Other news: ARRY +23.2% (reports top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma), GBSN +11.1% (USPTO has issued it a patent for compositions for signal amplification), CLSN +10.7% (receives Clinical Trial Application approval from the China FDA to conduct its ongoing Phase III OPTIMA Study), SCTY +8% (following analyst day), PRKR +5.9% (filed complaint with the ITC), HART +5.3% (announced 2.5 year $15 mln common stock purchase facility with Aspire Capital), MNOV +5.1% (received Fast Track designation from the FDA for MN-166 ), LL +3.3% (cont strength), DIS +2.2% (likely related to positive early reviews of upcoming biggest movie of all time), RPXC +2.1% (agrees to acquire privately-held Inventus Solutions for $232 million in cash; executing agreements to secure licensing rights for more than 20 companies in the portfolio of Round Rock Research; transaction is valued at more than $100 mln), CZR +1.8% (Fitch affirmed Caesars IDR at 'CC' & CERP/CGPH IDRs at 'B-'; Upgrades Corner Investment to 'B-), TGT +1% (Target and CVS Health completed Pharmacy and Clinic Businesses transaction), CVS +1% (Target and CVS Health completed Pharmacy and Clinic Businesses transaction; co also raised guidance), NQ +0.9% (approves the termination of its plan to divest of its equity interest in Beijing Tianya)
Analyst comments: PSO +4.7% (upgraded to Outperform from Neutral at Exane BNP Paribas), NOC +1.7% (upgraded to Overweight from Neutral at JP Morgan), CHRW +1.1% (upgraded to Buy at Stifel ), UACL +1% (upgraded to Buy at Stifel )